ArrowMark Colorado Holdings LLC Has $66.17 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

ArrowMark Colorado Holdings LLC grew its position in shares of Certara, Inc. (NASDAQ:CERT) by 164.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,213,278 shares of the company’s stock after acquiring an additional 3,861,674 shares during the quarter. ArrowMark Colorado Holdings LLC owned 3.86% of Certara worth $66,171,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC lifted its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its position in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in shares of Certara during the 4th quarter worth about $47,000. Blue Trust Inc. grew its holdings in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd increased its position in shares of Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company’s stock valued at $58,000 after acquiring an additional 3,656 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on CERT shares. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. KeyCorp boosted their target price on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, April 16th. Barclays cut their price target on shares of Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Finally, Stephens restated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Stock Performance

Shares of CERT stock opened at $12.99 on Friday. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.94. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -64.95, a PEG ratio of 9.29 and a beta of 1.64. The company has a 50-day simple moving average of $11.70 and a 200 day simple moving average of $11.65. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.